SidaGhanaV1, Istex, Corpus, bibRecord, 000089

Prevalence of persistent and latent viruses in untreated patients infected with HIV‐1 from Ghana, West Africa

Identifieur interne : 000089 ( Istex/Corpus ); précédent : 000088; suivant : 000090

Prevalence of persistent and latent viruses in untreated patients infected with HIV‐1 from Ghana, West Africa

Auteurs : Lara Isobel Compston ; Chengyao Li ; Francis Sarkodie ; Shirley Owusu-Ofori ; Ohene Opare-Sem ; Jean-Pierre Allain

Source :

Journal of Medical Virology [ 0146-6615 ] ; 2009-11.

RBID : ISTEX:5630810CCAEE5A5C636C1E3A8338507F90D61929

English descriptors

Abstract

Only limited epidemiological data, pertaining to the prevalence of common persistent viruses has been reported in Ghana. This study was conducted to determine the prevalence of persistent viruses in individuals with untreated HIV‐1 infection and uninfected blood donors. Paired plasma and cellular samples from HIV‐negative blood donors, asymptomatic HIV and symptomatic/AIDS cohorts were screened by multiplex PCR then qPCR for parvovirus B19 (B19V), hepatitis B virus (HBV), GB virus‐C (GBV‐C), cytomegalovirus (CMV), Epstein–Barr virus (EBV), human herpesvirus‐8 (HHV‐8) and varicella‐zoster virus (VZV). IgG antibodies specific to each target virus were tested to determine exposure rates. No evidence of viraemia was found for B19V and VZV in any group. Prevalence of GBV‐C plasma viraemia was significantly higher in asymptomatic and symptomatic HIV infection (16.7%) and (16.2%) than in blood donors (4%) P < 0.005. Occult HBV infection was significantly more frequent in symptomatic HIV infection (10.9%) compared to asymptomatic HIV (3.6%) and blood donors (1.6%) P < 0.005. Although there was a high background of EBV viraemia in cellular fractions of blood donors (8.3%), it was significantly higher in asymptomatic (44.6%) and symptomatic HIV (14.6%) P < 0.0001. For CMV, the significantly increased prevalence of viraemia was only observed in the plasma fraction of the symptomatic HIV‐1/AIDS patients (7.6%) compared to asymptomatic individuals (1.8%) and blood donors (0.8%) P ≤ 0.001. The background seroprevalence in blood donors was high for B19V (≥64%), HBV (≥70%), CMV and EBV (≥90%) and was significantly increased in HIV infections for HBV, CMV, VZV (symptomatic HIV), and HHV‐8 (asymptomatic and symptomatic HIV). J. Med. Virol. 81:1860–1868, 2009. © 2009 Wiley‐Liss, Inc.

Url:

https://api.istex.fr/document/5630810CCAEE5A5C636C1E3A8338507F90D61929/fulltext/pdf

DOI: 10.1002/jmv.21614

Links to Exploration step

ISTEX:5630810CCAEE5A5C636C1E3A8338507F90D61929

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prevalence of persistent and latent viruses in untreated patients infected with HIV‐1 from Ghana, West Africa</title>
<author><name sortKey="Compston, Lara Isobel" sort="Compston, Lara Isobel" uniqKey="Compston L" first="Lara Isobel" last="Compston">Lara Isobel Compston</name>
<affiliation><mods:affiliation>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre, Cambridge, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Chengyao" sort="Li, Chengyao" uniqKey="Li C" first="Chengyao" last="Li">Chengyao Li</name>
<affiliation><mods:affiliation>School of Biotechnology, Southern Medical University, Guangzhou, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Sarkodie, Francis" sort="Sarkodie, Francis" uniqKey="Sarkodie F" first="Francis" last="Sarkodie">Francis Sarkodie</name>
<affiliation><mods:affiliation>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Owusu Fori, Shirley" sort="Owusu Fori, Shirley" uniqKey="Owusu Fori S" first="Shirley" last="Owusu-Ofori">Shirley Owusu-Ofori</name>
<affiliation><mods:affiliation>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Opare Em, Ohene" sort="Opare Em, Ohene" uniqKey="Opare Em O" first="Ohene" last="Opare-Sem">Ohene Opare-Sem</name>
<affiliation><mods:affiliation>Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Allain, Jean Ierre" sort="Allain, Jean Ierre" uniqKey="Allain J" first="Jean-Pierre" last="Allain">Jean-Pierre Allain</name>
<affiliation><mods:affiliation>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre, Cambridge, United Kingdom</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Cambridge Blood Centre, Long Rd, Long Road, Cambridge CB2 2PT, UK.===</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5630810CCAEE5A5C636C1E3A8338507F90D61929</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/jmv.21614</idno>
<idno type="url">https://api.istex.fr/document/5630810CCAEE5A5C636C1E3A8338507F90D61929/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000089</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000089</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Prevalence of persistent and latent viruses in untreated patients infected with HIV‐1 from Ghana, West Africa</title>
<author><name sortKey="Compston, Lara Isobel" sort="Compston, Lara Isobel" uniqKey="Compston L" first="Lara Isobel" last="Compston">Lara Isobel Compston</name>
<affiliation><mods:affiliation>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre, Cambridge, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Chengyao" sort="Li, Chengyao" uniqKey="Li C" first="Chengyao" last="Li">Chengyao Li</name>
<affiliation><mods:affiliation>School of Biotechnology, Southern Medical University, Guangzhou, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Sarkodie, Francis" sort="Sarkodie, Francis" uniqKey="Sarkodie F" first="Francis" last="Sarkodie">Francis Sarkodie</name>
<affiliation><mods:affiliation>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Owusu Fori, Shirley" sort="Owusu Fori, Shirley" uniqKey="Owusu Fori S" first="Shirley" last="Owusu-Ofori">Shirley Owusu-Ofori</name>
<affiliation><mods:affiliation>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Opare Em, Ohene" sort="Opare Em, Ohene" uniqKey="Opare Em O" first="Ohene" last="Opare-Sem">Ohene Opare-Sem</name>
<affiliation><mods:affiliation>Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Allain, Jean Ierre" sort="Allain, Jean Ierre" uniqKey="Allain J" first="Jean-Pierre" last="Allain">Jean-Pierre Allain</name>
<affiliation><mods:affiliation>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre, Cambridge, United Kingdom</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Cambridge Blood Centre, Long Rd, Long Road, Cambridge CB2 2PT, UK.===</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Journal of Medical Virology</title>
<title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title>
<idno type="ISSN">0146-6615</idno>
<idno type="eISSN">1096-9071</idno>
<imprint><biblScope unit="vol">81</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1860">1860</biblScope>
<biblScope unit="page" to="1868">1868</biblScope>
<biblScope unit="page-count">9</biblScope>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-11">2009-11</date>
</imprint>
<idno type="ISSN">0146-6615</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0146-6615</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibody prevalence</term>
<term>Antibody response</term>
<term>Assay</term>
<term>Asymptomatic</term>
<term>Background prevalence</term>
<term>Baseline odds</term>
<term>Black boxes</term>
<term>Blood donor</term>
<term>Blood donor controls</term>
<term>Blood donor group</term>
<term>Blood donors</term>
<term>Bold donor controls</term>
<term>Bone marrow</term>
<term>Cambridge blood centre</term>
<term>Cell count</term>
<term>Cellular</term>
<term>Cellular fraction</term>
<term>Cellular samples</term>
<term>Clin</term>
<term>Clin microbiol</term>
<term>Clinical implications</term>
<term>Clinical stage</term>
<term>Cohort</term>
<term>Compston</term>
<term>Control group</term>
<term>Detectable viraemia</term>
<term>Donor</term>
<term>Exact test</term>
<term>Ghanaian blood donors</term>
<term>Grant sponsor</term>
<term>Gray boxes</term>
<term>Healthy blood donors</term>
<term>Hepatitis</term>
<term>Herpesvirus</term>
<term>Human herpesvirus</term>
<term>Human virus</term>
<term>Immune</term>
<term>Immune restoration disease</term>
<term>Important role</term>
<term>Infection</term>
<term>Komfo anokye teaching hospital</term>
<term>Natural history</term>
<term>Occult</term>
<term>Occult hepatitis</term>
<term>Odds ratio</term>
<term>Odds ratios</term>
<term>Opportunistic infection</term>
<term>Opportunistic infections</term>
<term>Overall prevalence</term>
<term>Parvovirus</term>
<term>Peripheral blood</term>
<term>Persistent viruses</term>
<term>Plasma fraction</term>
<term>Plasma samples</term>
<term>Plasma viraemia</term>
<term>Positive cohorts</term>
<term>Positive groups</term>
<term>Potential marker</term>
<term>Potential reactivation</term>
<term>Predictor</term>
<term>Prevalence</term>
<term>Prospective study</term>
<term>Reactivation</term>
<term>Risk factors</term>
<term>Roche diagnostics</term>
<term>Seroprevalence</term>
<term>Sexual transmission</term>
<term>Single virus</term>
<term>Symptomatic group</term>
<term>Symptomatic patients</term>
<term>Target virus</term>
<term>Total number</term>
<term>Transmission routes</term>
<term>Untreated patients</term>
<term>Useful guide</term>
<term>Viraemia</term>
<term>Viraemia prevalence</term>
<term>Viral</term>
<term>Viral load</term>
<term>Viral markers</term>
<term>Viral reactivation</term>
<term>Viral replication</term>
<term>Virol</term>
<term>Virus</term>
<term>Virus infection</term>
<term>Virus load</term>
<term>Whole blood</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Antibody prevalence</term>
<term>Antibody response</term>
<term>Assay</term>
<term>Asymptomatic</term>
<term>Background prevalence</term>
<term>Baseline odds</term>
<term>Black boxes</term>
<term>Blood donor</term>
<term>Blood donor controls</term>
<term>Blood donor group</term>
<term>Blood donors</term>
<term>Bold donor controls</term>
<term>Bone marrow</term>
<term>Cambridge blood centre</term>
<term>Cell count</term>
<term>Cellular</term>
<term>Cellular fraction</term>
<term>Cellular samples</term>
<term>Clin</term>
<term>Clin microbiol</term>
<term>Clinical implications</term>
<term>Clinical stage</term>
<term>Cohort</term>
<term>Compston</term>
<term>Control group</term>
<term>Detectable viraemia</term>
<term>Donor</term>
<term>Exact test</term>
<term>Ghanaian blood donors</term>
<term>Grant sponsor</term>
<term>Gray boxes</term>
<term>Healthy blood donors</term>
<term>Hepatitis</term>
<term>Herpesvirus</term>
<term>Human herpesvirus</term>
<term>Human virus</term>
<term>Immune</term>
<term>Immune restoration disease</term>
<term>Important role</term>
<term>Infection</term>
<term>Komfo anokye teaching hospital</term>
<term>Natural history</term>
<term>Occult</term>
<term>Occult hepatitis</term>
<term>Odds ratio</term>
<term>Odds ratios</term>
<term>Opportunistic infection</term>
<term>Opportunistic infections</term>
<term>Overall prevalence</term>
<term>Parvovirus</term>
<term>Peripheral blood</term>
<term>Persistent viruses</term>
<term>Plasma fraction</term>
<term>Plasma samples</term>
<term>Plasma viraemia</term>
<term>Positive cohorts</term>
<term>Positive groups</term>
<term>Potential marker</term>
<term>Potential reactivation</term>
<term>Predictor</term>
<term>Prevalence</term>
<term>Prospective study</term>
<term>Reactivation</term>
<term>Risk factors</term>
<term>Roche diagnostics</term>
<term>Seroprevalence</term>
<term>Sexual transmission</term>
<term>Single virus</term>
<term>Symptomatic group</term>
<term>Symptomatic patients</term>
<term>Target virus</term>
<term>Total number</term>
<term>Transmission routes</term>
<term>Untreated patients</term>
<term>Useful guide</term>
<term>Viraemia</term>
<term>Viraemia prevalence</term>
<term>Viral</term>
<term>Viral load</term>
<term>Viral markers</term>
<term>Viral reactivation</term>
<term>Viral replication</term>
<term>Virol</term>
<term>Virus</term>
<term>Virus infection</term>
<term>Virus load</term>
<term>Whole blood</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Only limited epidemiological data, pertaining to the prevalence of common persistent viruses has been reported in Ghana. This study was conducted to determine the prevalence of persistent viruses in individuals with untreated HIV‐1 infection and uninfected blood donors. Paired plasma and cellular samples from HIV‐negative blood donors, asymptomatic HIV and symptomatic/AIDS cohorts were screened by multiplex PCR then qPCR for parvovirus B19 (B19V), hepatitis B virus (HBV), GB virus‐C (GBV‐C), cytomegalovirus (CMV), Epstein–Barr virus (EBV), human herpesvirus‐8 (HHV‐8) and varicella‐zoster virus (VZV). IgG antibodies specific to each target virus were tested to determine exposure rates. No evidence of viraemia was found for B19V and VZV in any group. Prevalence of GBV‐C plasma viraemia was significantly higher in asymptomatic and symptomatic HIV infection (16.7%) and (16.2%) than in blood donors (4%) P < 0.005. Occult HBV infection was significantly more frequent in symptomatic HIV infection (10.9%) compared to asymptomatic HIV (3.6%) and blood donors (1.6%) P < 0.005. Although there was a high background of EBV viraemia in cellular fractions of blood donors (8.3%), it was significantly higher in asymptomatic (44.6%) and symptomatic HIV (14.6%) P < 0.0001. For CMV, the significantly increased prevalence of viraemia was only observed in the plasma fraction of the symptomatic HIV‐1/AIDS patients (7.6%) compared to asymptomatic individuals (1.8%) and blood donors (0.8%) P ≤ 0.001. The background seroprevalence in blood donors was high for B19V (≥64%), HBV (≥70%), CMV and EBV (≥90%) and was significantly increased in HIV infections for HBV, CMV, VZV (symptomatic HIV), and HHV‐8 (asymptomatic and symptomatic HIV). J. Med. Virol. 81:1860–1868, 2009. © 2009 Wiley‐Liss, Inc.</div>
</front>
</TEI>
<istex><corpusName>wiley</corpusName>
<keywords><teeft><json:string>viraemia</json:string>
<json:string>viral</json:string>
<json:string>cohort</json:string>
<json:string>reactivation</json:string>
<json:string>asymptomatic</json:string>
<json:string>virol</json:string>
<json:string>viral load</json:string>
<json:string>seroprevalence</json:string>
<json:string>occult</json:string>
<json:string>clin</json:string>
<json:string>blood donors</json:string>
<json:string>parvovirus</json:string>
<json:string>antibody prevalence</json:string>
<json:string>symptomatic patients</json:string>
<json:string>persistent viruses</json:string>
<json:string>cellular fraction</json:string>
<json:string>compston</json:string>
<json:string>herpesvirus</json:string>
<json:string>predictor</json:string>
<json:string>immune</json:string>
<json:string>prevalence</json:string>
<json:string>healthy blood donors</json:string>
<json:string>assay</json:string>
<json:string>odds ratios</json:string>
<json:string>plasma fraction</json:string>
<json:string>blood donor controls</json:string>
<json:string>odds ratio</json:string>
<json:string>opportunistic infections</json:string>
<json:string>occult hepatitis</json:string>
<json:string>exact test</json:string>
<json:string>viral reactivation</json:string>
<json:string>virus infection</json:string>
<json:string>donor</json:string>
<json:string>plasma viraemia</json:string>
<json:string>plasma samples</json:string>
<json:string>risk factors</json:string>
<json:string>prospective study</json:string>
<json:string>potential reactivation</json:string>
<json:string>positive cohorts</json:string>
<json:string>antibody response</json:string>
<json:string>viral markers</json:string>
<json:string>viraemia prevalence</json:string>
<json:string>peripheral blood</json:string>
<json:string>detectable viraemia</json:string>
<json:string>sexual transmission</json:string>
<json:string>natural history</json:string>
<json:string>virus</json:string>
<json:string>hepatitis</json:string>
<json:string>infection</json:string>
<json:string>cellular</json:string>
<json:string>bone marrow</json:string>
<json:string>single virus</json:string>
<json:string>cambridge blood centre</json:string>
<json:string>background prevalence</json:string>
<json:string>roche diagnostics</json:string>
<json:string>clinical stage</json:string>
<json:string>overall prevalence</json:string>
<json:string>opportunistic infection</json:string>
<json:string>symptomatic group</json:string>
<json:string>grant sponsor</json:string>
<json:string>positive groups</json:string>
<json:string>komfo anokye teaching hospital</json:string>
<json:string>blood donor</json:string>
<json:string>cellular samples</json:string>
<json:string>target virus</json:string>
<json:string>total number</json:string>
<json:string>potential marker</json:string>
<json:string>blood donor group</json:string>
<json:string>baseline odds</json:string>
<json:string>useful guide</json:string>
<json:string>black boxes</json:string>
<json:string>bold donor controls</json:string>
<json:string>gray boxes</json:string>
<json:string>transmission routes</json:string>
<json:string>ghanaian blood donors</json:string>
<json:string>viral replication</json:string>
<json:string>cell count</json:string>
<json:string>immune restoration disease</json:string>
<json:string>important role</json:string>
<json:string>untreated patients</json:string>
<json:string>virus load</json:string>
<json:string>human virus</json:string>
<json:string>clin microbiol</json:string>
<json:string>human herpesvirus</json:string>
<json:string>whole blood</json:string>
<json:string>clinical implications</json:string>
<json:string>control group</json:string>
</teeft>
</keywords>
<author><json:item><name>Lara Isobel Compston</name>
<affiliations><json:string>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre, Cambridge, United Kingdom</json:string>
</affiliations>
</json:item>
<json:item><name>Chengyao Li</name>
<affiliations><json:string>School of Biotechnology, Southern Medical University, Guangzhou, China</json:string>
</affiliations>
</json:item>
<json:item><name>Francis Sarkodie</name>
<affiliations><json:string>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana</json:string>
</affiliations>
</json:item>
<json:item><name>Shirley Owusu‐Ofori</name>
<affiliations><json:string>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana</json:string>
</affiliations>
</json:item>
<json:item><name>Ohene Opare‐Sem</name>
<affiliations><json:string>Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana</json:string>
</affiliations>
</json:item>
<json:item><name>Jean‐Pierre Allain</name>
<affiliations><json:string>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre, Cambridge, United Kingdom</json:string>
<json:string>Cambridge Blood Centre, Long Rd, Long Road, Cambridge CB2 2PT, UK.===</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>HIV</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>immunodeficiency</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>herpesviruses</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Hepatitis B Virus (HBV)</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>occult hepatitis B infection</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>GB virus‐C (GBV‐C)</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>parvovirus B19V</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Sub‐Saharan Africa</value>
</json:item>
</subject>
<articleId><json:string>JMV21614</json:string>
</articleId>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>article</json:string>
</originalGenre>
<abstract>Only limited epidemiological data, pertaining to the prevalence of common persistent viruses has been reported in Ghana. This study was conducted to determine the prevalence of persistent viruses in individuals with untreated HIV‐1 infection and uninfected blood donors. Paired plasma and cellular samples from HIV‐negative blood donors, asymptomatic HIV and symptomatic/AIDS cohorts were screened by multiplex PCR then qPCR for parvovirus B19 (B19V), hepatitis B virus (HBV), GB virus‐C (GBV‐C), cytomegalovirus (CMV), Epstein–Barr virus (EBV), human herpesvirus‐8 (HHV‐8) and varicella‐zoster virus (VZV). IgG antibodies specific to each target virus were tested to determine exposure rates. No evidence of viraemia was found for B19V and VZV in any group. Prevalence of GBV‐C plasma viraemia was significantly higher in asymptomatic and symptomatic HIV infection (16.7%) and (16.2%) than in blood donors (4%) P > 0.005. Occult HBV infection was significantly more frequent in symptomatic HIV infection (10.9%) compared to asymptomatic HIV (3.6%) and blood donors (1.6%) P > 0.005. Although there was a high background of EBV viraemia in cellular fractions of blood donors (8.3%), it was significantly higher in asymptomatic (44.6%) and symptomatic HIV (14.6%) P > 0.0001. For CMV, the significantly increased prevalence of viraemia was only observed in the plasma fraction of the symptomatic HIV‐1/AIDS patients (7.6%) compared to asymptomatic individuals (1.8%) and blood donors (0.8%) P ≤ 0.001. The background seroprevalence in blood donors was high for B19V (≥64%), HBV (≥70%), CMV and EBV (≥90%) and was significantly increased in HIV infections for HBV, CMV, VZV (symptomatic HIV), and HHV‐8 (asymptomatic and symptomatic HIV). J. Med. Virol. 81:1860–1868, 2009. © 2009 Wiley‐Liss, Inc.</abstract>
<qualityIndicators><score>8</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>594 x 792 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractCharCount>1795</abstractCharCount>
<pdfWordCount>5480</pdfWordCount>
<pdfCharCount>35914</pdfCharCount>
<pdfPageCount>9</pdfPageCount>
<abstractWordCount>257</abstractWordCount>
</qualityIndicators>
<title>Prevalence of persistent and latent viruses in untreated patients infected with HIV‐1 from Ghana, West Africa</title>
<genre><json:string>article</json:string>
</genre>
<host><title>Journal of Medical Virology</title>
<language><json:string>unknown</json:string>
</language>
<doi><json:string>10.1002/(ISSN)1096-9071</json:string>
</doi>
<issn><json:string>0146-6615</json:string>
</issn>
<eissn><json:string>1096-9071</json:string>
</eissn>
<publisherId><json:string>JMV</json:string>
</publisherId>
<volume>81</volume>
<issue>11</issue>
<pages><first>1860</first>
<last>1868</last>
<total>9</total>
</pages>
<genre><json:string>journal</json:string>
</genre>
<subject><json:item><value>Research Article</value>
</json:item>
</subject>
</host>
<categories><wos><json:string>science</json:string>
<json:string>virology</json:string>
</wos>
<scienceMetrix><json:string>health sciences</json:string>
<json:string>biomedical research</json:string>
<json:string>virology</json:string>
</scienceMetrix>
<inist><json:string>sciences appliquees, technologies et medecines</json:string>
<json:string>sciences biologiques et medicales</json:string>
<json:string>sciences medicales</json:string>
<json:string>pathologie infectieuse</json:string>
</inist>
</categories>
<publicationDate>2009</publicationDate>
<copyrightDate>2009</copyrightDate>
<doi><json:string>10.1002/jmv.21614</json:string>
</doi>
<id>5630810CCAEE5A5C636C1E3A8338507F90D61929</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/5630810CCAEE5A5C636C1E3A8338507F90D61929/fulltext/pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/5630810CCAEE5A5C636C1E3A8338507F90D61929/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/5630810CCAEE5A5C636C1E3A8338507F90D61929/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Prevalence of persistent and latent viruses in untreated patients infected with HIV‐1 from Ghana, West Africa</title>
</titleStmt>
<publicationStmt><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<availability><licence>Copyright © 2009 Wiley‐Liss, Inc.</licence>
</availability>
<date type="published" when="2009-11"></date>
</publicationStmt>
<notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note>
<note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">Prevalence of persistent and latent viruses in untreated patients infected with HIV‐1 from Ghana, West Africa</title>
<title level="a" type="short" xml:lang="en">Prevalence of Persistent Viruses in HIV</title>
<author xml:id="author-0000"><persName><forename type="first">Lara Isobel</forename>
<surname>Compston</surname>
</persName>
<affiliation>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre, Cambridge, United Kingdom<address><country key="GB"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0001"><persName><forename type="first">Chengyao</forename>
<surname>Li</surname>
</persName>
<affiliation>School of Biotechnology, Southern Medical University, Guangzhou, China<address><country key="CN"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0002"><persName><forename type="first">Francis</forename>
<surname>Sarkodie</surname>
</persName>
<affiliation>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana<address><country key="GH"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0003"><persName><forename type="first">Shirley</forename>
<surname>Owusu‐Ofori</surname>
</persName>
<affiliation>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana<address><country key="GH"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0004"><persName><forename type="first">Ohene</forename>
<surname>Opare‐Sem</surname>
</persName>
<affiliation>Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana<address><country key="GH"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0005" role="corresp"><persName><forename type="first">Jean‐Pierre</forename>
<surname>Allain</surname>
</persName>
<email>jpa1000@cam.ac.uk</email>
<affiliation>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre, Cambridge, United Kingdom<address><country key="GB"></country>
</address>
</affiliation>
<affiliation>Cambridge Blood Centre, Long Rd, Long Road, Cambridge CB2 2PT, UK.===</affiliation>
</author>
<idno type="istex">5630810CCAEE5A5C636C1E3A8338507F90D61929</idno>
<idno type="DOI">10.1002/jmv.21614</idno>
<idno type="unit">JMV21614</idno>
<idno type="toTypesetVersion">file:JMV.JMV21614.pdf</idno>
</analytic>
<monogr><title level="j" type="main">Journal of Medical Virology</title>
<title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title>
<idno type="pISSN">0146-6615</idno>
<idno type="eISSN">1096-9071</idno>
<idno type="book-DOI">10.1002/(ISSN)1096-9071</idno>
<idno type="book-part-DOI">10.1002/jmv.v81:11</idno>
<idno type="product">JMV</idno>
<imprint><biblScope unit="vol">81</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1860">1860</biblScope>
<biblScope unit="page" to="1868">1868</biblScope>
<biblScope unit="page-count">9</biblScope>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-11"></date>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head>
<p>Only limited epidemiological data, pertaining to the prevalence of common persistent viruses has been reported in Ghana. This study was conducted to determine the prevalence of persistent viruses in individuals with untreated HIV‐1 infection and uninfected blood donors. Paired plasma and cellular samples from HIV‐negative blood donors, asymptomatic HIV and symptomatic/AIDS cohorts were screened by multiplex PCR then qPCR for parvovirus B19 (B19V), hepatitis B virus (HBV), GB virus‐C (GBV‐C), cytomegalovirus (CMV), Epstein–Barr virus (EBV), human herpesvirus‐8 (HHV‐8) and varicella‐zoster virus (VZV). IgG antibodies specific to each target virus were tested to determine exposure rates. No evidence of viraemia was found for B19V and VZV in any group. Prevalence of GBV‐C plasma viraemia was significantly higher in asymptomatic and symptomatic HIV infection (16.7%) and (16.2%) than in blood donors (4%) <hi rend="italic">P</hi>
 < 0.005. Occult HBV infection was significantly more frequent in symptomatic HIV infection (10.9%) compared to asymptomatic HIV (3.6%) and blood donors (1.6%) <hi rend="italic">P</hi>
 < 0.005. Although there was a high background of EBV viraemia in cellular fractions of blood donors (8.3%), it was significantly higher in asymptomatic (44.6%) and symptomatic HIV (14.6%) <hi rend="italic">P</hi>
 < 0.0001. For CMV, the significantly increased prevalence of viraemia was only observed in the plasma fraction of the symptomatic HIV‐1/AIDS patients (7.6%) compared to asymptomatic individuals (1.8%) and blood donors (0.8%) <hi rend="italic">P</hi>
 ≤ 0.001. The background seroprevalence in blood donors was high for B19V (≥64%), HBV (≥70%), CMV and EBV (≥90%) and was significantly increased in HIV infections for HBV, CMV, VZV (symptomatic HIV), and HHV‐8 (asymptomatic and symptomatic HIV). J. Med. Virol. 81:1860–1868, 2009. © 2009 Wiley‐Liss, Inc.</p>
</abstract>
<textClass><keywords xml:lang="en"><term xml:id="kwd1">HIV</term>
<term xml:id="kwd2">immunodeficiency</term>
<term xml:id="kwd3">herpesviruses</term>
<term xml:id="kwd4">Hepatitis B Virus (HBV)</term>
<term xml:id="kwd5">occult hepatitis B infection</term>
<term xml:id="kwd6">GB virus‐C (GBV‐C)</term>
<term xml:id="kwd7">parvovirus B19V</term>
<term xml:id="kwd8">Sub‐Saharan Africa</term>
</keywords>
<classCode scheme="articleCategory">Research Article</classCode>
</textClass>
<langUsage><language ident="EN"></language>
</langUsage>
</profileDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/5630810CCAEE5A5C636C1E3A8338507F90D61929/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName>
<publisherLoc>Hoboken</publisherLoc>
</publisherInfo>
<doi registered="yes">10.1002/(ISSN)1096-9071</doi>
<issn type="print">0146-6615</issn>
<issn type="electronic">1096-9071</issn>
<idGroup><id type="product" value="JMV"></id>
</idGroup>
<titleGroup><title type="main" xml:lang="en" sort="JOURNAL OF MEDICAL VIROLOGY">Journal of Medical Virology</title>
<title type="short">J. Med. Virol.</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="110"><doi origin="wiley" registered="yes">10.1002/jmv.v81:11</doi>
<numberingGroup><numbering type="journalVolume" number="81">81</numbering>
<numbering type="journalIssue">11</numbering>
</numberingGroup>
<coverDate startDate="2009-11">November 2009</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="article" position="30" status="forIssue"><doi origin="wiley" registered="yes">10.1002/jmv.21614</doi>
<idGroup><id type="unit" value="JMV21614"></id>
</idGroup>
<countGroup><count type="pageTotal" number="9"></count>
</countGroup>
<titleGroup><title type="articleCategory">Research Article</title>
</titleGroup>
<copyright ownership="publisher">Copyright © 2009 Wiley‐Liss, Inc.</copyright>
<eventGroup><event type="manuscriptAccepted" date="2009-06-30"></event>
<event type="firstOnline" date="2009-09-22"></event>
<event type="publishedOnlineFinalForm" date="2009-09-22"></event>
<event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-15"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-20"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-30"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst">1860</numbering>
<numbering type="pageLast">1868</numbering>
</numberingGroup>
<correspondenceTo>Cambridge Blood Centre, Long Rd, Long Road, Cambridge CB2 2PT, UK.===</correspondenceTo>
<linkGroup><link type="toTypesetVersion" href="file:JMV.JMV21614.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><countGroup><count type="figureTotal" number="2"></count>
<count type="tableTotal" number="2"></count>
<count type="referenceTotal" number="50"></count>
<count type="wordTotal" number="1667"></count>
</countGroup>
<titleGroup><title type="main" xml:lang="en">Prevalence of persistent and latent viruses in untreated patients infected with HIV‐1 from Ghana, West Africa</title>
<title type="short" xml:lang="en">Prevalence of Persistent Viruses in HIV</title>
</titleGroup>
<creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Lara Isobel</givenNames>
<familyName>Compston</familyName>
</personName>
</creator>
<creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Chengyao</givenNames>
<familyName>Li</familyName>
</personName>
</creator>
<creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Francis</givenNames>
<familyName>Sarkodie</familyName>
</personName>
</creator>
<creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Shirley</givenNames>
<familyName>Owusu‐Ofori</familyName>
</personName>
</creator>
<creator xml:id="au5" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Ohene</givenNames>
<familyName>Opare‐Sem</familyName>
</personName>
</creator>
<creator xml:id="au6" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Jean‐Pierre</givenNames>
<familyName>Allain</familyName>
</personName>
<contactDetails><email>jpa1000@cam.ac.uk</email>
</contactDetails>
</creator>
</creators>
<affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre, Cambridge, United Kingdom</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af2" countryCode="CN" type="organization"><unparsedAffiliation>School of Biotechnology, Southern Medical University, Guangzhou, China</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af3" countryCode="GH" type="organization"><unparsedAffiliation>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af4" countryCode="GH" type="organization"><unparsedAffiliation>Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">HIV</keyword>
<keyword xml:id="kwd2">immunodeficiency</keyword>
<keyword xml:id="kwd3">herpesviruses</keyword>
<keyword xml:id="kwd4">Hepatitis B Virus (HBV)</keyword>
<keyword xml:id="kwd5">occult hepatitis B infection</keyword>
<keyword xml:id="kwd6">GB virus‐C (GBV‐C)</keyword>
<keyword xml:id="kwd7">parvovirus B19V</keyword>
<keyword xml:id="kwd8">Sub‐Saharan Africa</keyword>
</keywordGroup>
<fundingInfo><fundingAgency>National Health Service Blood and Transplant as a PhD grant (partial to L.I.C.)</fundingAgency>
</fundingInfo>
<fundingInfo><fundingAgency>European Union Framework VI, SSP, BOTIA</fundingAgency>
<fundingNumber>SP23‐CT‐2006‐006487</fundingNumber>
</fundingInfo>
<abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title>
<p>Only limited epidemiological data, pertaining to the prevalence of common persistent viruses has been reported in Ghana. This study was conducted to determine the prevalence of persistent viruses in individuals with untreated HIV‐1 infection and uninfected blood donors. Paired plasma and cellular samples from HIV‐negative blood donors, asymptomatic HIV and symptomatic/AIDS cohorts were screened by multiplex PCR then qPCR for parvovirus B19 (B19V), hepatitis B virus (HBV), GB virus‐C (GBV‐C), cytomegalovirus (CMV), Epstein–Barr virus (EBV), human herpesvirus‐8 (HHV‐8) and varicella‐zoster virus (VZV). IgG antibodies specific to each target virus were tested to determine exposure rates. No evidence of viraemia was found for B19V and VZV in any group. Prevalence of GBV‐C plasma viraemia was significantly higher in asymptomatic and symptomatic HIV infection (16.7%) and (16.2%) than in blood donors (4%) <i>P</i>
 < 0.005. Occult HBV infection was significantly more frequent in symptomatic HIV infection (10.9%) compared to asymptomatic HIV (3.6%) and blood donors (1.6%) <i>P</i>
 < 0.005. Although there was a high background of EBV viraemia in cellular fractions of blood donors (8.3%), it was significantly higher in asymptomatic (44.6%) and symptomatic HIV (14.6%) <i>P</i>
 < 0.0001. For CMV, the significantly increased prevalence of viraemia was only observed in the plasma fraction of the symptomatic HIV‐1/AIDS patients (7.6%) compared to asymptomatic individuals (1.8%) and blood donors (0.8%) <i>P</i>
 ≤ 0.001. The background seroprevalence in blood donors was high for B19V (≥64%), HBV (≥70%), CMV and EBV (≥90%) and was significantly increased in HIV infections for HBV, CMV, VZV (symptomatic HIV), and HHV‐8 (asymptomatic and symptomatic HIV). J. Med. Virol. 81:1860–1868, 2009. © 2009 Wiley‐Liss, Inc.</p>
</abstract>
</abstractGroup>
</contentMeta>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Prevalence of persistent and latent viruses in untreated patients infected with HIV‐1 from Ghana, West Africa</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en"><title>Prevalence of Persistent Viruses in HIV</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>Prevalence of persistent and latent viruses in untreated patients infected with HIV‐1 from Ghana, West Africa</title>
</titleInfo>
<name type="personal"><namePart type="given">Lara Isobel</namePart>
<namePart type="family">Compston</namePart>
<affiliation>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre, Cambridge, United Kingdom</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Chengyao</namePart>
<namePart type="family">Li</namePart>
<affiliation>School of Biotechnology, Southern Medical University, Guangzhou, China</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Francis</namePart>
<namePart type="family">Sarkodie</namePart>
<affiliation>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Shirley</namePart>
<namePart type="family">Owusu‐Ofori</namePart>
<affiliation>Transfusion Medicine Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Ohene</namePart>
<namePart type="family">Opare‐Sem</namePart>
<affiliation>Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Jean‐Pierre</namePart>
<namePart type="family">Allain</namePart>
<affiliation>Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge Blood Centre, Cambridge, United Kingdom</affiliation>
<affiliation>Cambridge Blood Centre, Long Rd, Long Road, Cambridge CB2 2PT, UK.===</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="article" displayLabel="article"></genre>
<originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<place><placeTerm type="text">Hoboken</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2009-11</dateIssued>
<dateValid encoding="w3cdtf">2009-06-30</dateValid>
<copyrightDate encoding="w3cdtf">2009</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
<extent unit="figures">2</extent>
<extent unit="tables">2</extent>
<extent unit="references">50</extent>
<extent unit="words">1667</extent>
</physicalDescription>
<abstract lang="en">Only limited epidemiological data, pertaining to the prevalence of common persistent viruses has been reported in Ghana. This study was conducted to determine the prevalence of persistent viruses in individuals with untreated HIV‐1 infection and uninfected blood donors. Paired plasma and cellular samples from HIV‐negative blood donors, asymptomatic HIV and symptomatic/AIDS cohorts were screened by multiplex PCR then qPCR for parvovirus B19 (B19V), hepatitis B virus (HBV), GB virus‐C (GBV‐C), cytomegalovirus (CMV), Epstein–Barr virus (EBV), human herpesvirus‐8 (HHV‐8) and varicella‐zoster virus (VZV). IgG antibodies specific to each target virus were tested to determine exposure rates. No evidence of viraemia was found for B19V and VZV in any group. Prevalence of GBV‐C plasma viraemia was significantly higher in asymptomatic and symptomatic HIV infection (16.7%) and (16.2%) than in blood donors (4%) P < 0.005. Occult HBV infection was significantly more frequent in symptomatic HIV infection (10.9%) compared to asymptomatic HIV (3.6%) and blood donors (1.6%) P < 0.005. Although there was a high background of EBV viraemia in cellular fractions of blood donors (8.3%), it was significantly higher in asymptomatic (44.6%) and symptomatic HIV (14.6%) P < 0.0001. For CMV, the significantly increased prevalence of viraemia was only observed in the plasma fraction of the symptomatic HIV‐1/AIDS patients (7.6%) compared to asymptomatic individuals (1.8%) and blood donors (0.8%) P ≤ 0.001. The background seroprevalence in blood donors was high for B19V (≥64%), HBV (≥70%), CMV and EBV (≥90%) and was significantly increased in HIV infections for HBV, CMV, VZV (symptomatic HIV), and HHV‐8 (asymptomatic and symptomatic HIV). J. Med. Virol. 81:1860–1868, 2009. © 2009 Wiley‐Liss, Inc.</abstract>
<note type="funding">National Health Service Blood and Transplant as a PhD grant (partial to L.I.C.)</note>
<note type="funding">European Union Framework VI, SSP, BOTIA - No. SP23‐CT‐2006‐006487; </note>
<subject lang="en"><genre>keywords</genre>
<topic>HIV</topic>
<topic>immunodeficiency</topic>
<topic>herpesviruses</topic>
<topic>Hepatitis B Virus (HBV)</topic>
<topic>occult hepatitis B infection</topic>
<topic>GB virus‐C (GBV‐C)</topic>
<topic>parvovirus B19V</topic>
<topic>Sub‐Saharan Africa</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Journal of Medical Virology</title>
</titleInfo>
<titleInfo type="abbreviated"><title>J. Med. Virol.</title>
</titleInfo>
<genre type="journal">journal</genre>
<subject><genre>article-category</genre>
<topic>Research Article</topic>
</subject>
<identifier type="ISSN">0146-6615</identifier>
<identifier type="eISSN">1096-9071</identifier>
<identifier type="DOI">10.1002/(ISSN)1096-9071</identifier>
<identifier type="PublisherID">JMV</identifier>
<part><date>2009</date>
<detail type="volume"><caption>vol.</caption>
<number>81</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>11</number>
</detail>
<extent unit="pages"><start>1860</start>
<end>1868</end>
<total>9</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">5630810CCAEE5A5C636C1E3A8338507F90D61929</identifier>
<identifier type="DOI">10.1002/jmv.21614</identifier>
<identifier type="ArticleID">JMV21614</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Wiley‐Liss, Inc.</accessCondition>
<recordInfo><recordContentSource>WILEY</recordContentSource>
<recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin>
</recordInfo>
</mods>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000089 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000089 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaGhanaV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:5630810CCAEE5A5C636C1E3A8338507F90D61929
   |texte=   Prevalence of persistent and latent viruses in untreated patients infected with HIV‐1 from Ghana, West Africa
}}

This area was generated with Dilib version V0.6.31.
Data generation: Tue Nov 7 18:07:38 2017. Site generation: Tue Mar 5 15:01:57 2024

	Le SIDA au Ghana (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Le SIDA au Ghana (serveur d'exploration)

Prevalence of persistent and latent viruses in untreated patients infected with HIV‐1 from Ghana, West Africa

Prevalence of persistent and latent viruses in untreated patients infected with HIV‐1 from Ghana, West Africa

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri